OTLK - Outlook Therapeutics, Inc.
| Previous Close | 1.3000 |
| Open | 1.3400 |
| Bid | 1.3000 x 800 |
| Ask | 1.3600 x 800 |
| Day's Range | 1.2800 - 1.3600 |
| 52 Week Range | 0.8500 - 10.9600 |
| Volume | 66,745 |
| Avg. Volume | 304,092 |
| Market Cap | 37.551M |
| Beta (3Y Monthly) | -0.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.8860 |
| Earnings Date | Dec 16, 2019 - Dec 20, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.25 |
- GlobeNewswire
Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference
CRANBURY, N.J., Sept. 11, 2019 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it is scheduled to participate in the Ladenburg Thalmann 2019.
- GlobeNewswire
Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference
CRANBURY, N.J., Aug. 27, 2019 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it is scheduled to participate in the H.C. Wainwright 21st.
- GlobeNewswire
Outlook Therapeutics Completes Patient Enrollment for NORSE 1 a Phase 3 Clinical Trial for ONS-5010 in Wet AMD
Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, an ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that it has completed patient enrollment in the NORSE 1 Phase 3 clinical trial, which is evaluating ONS-5010 against ranibizumab (Lucentis®) for wet AMD. “We are pleased with the building momentum in our two ongoing Phase 3 clinical trials for ONS-5010, including completing enrollment in NORSE 1. The study is the first of two ongoing, adequate and well controlled Phase 3 clinical trials evaluating ONS-5010 against ranibizumab for wet AMD.
- GlobeNewswire
Outlook Therapeutics Provides Business Update and Reports Financial Results for Third Quarter of Fiscal 2019
CRANBURY, N.J., Aug. 14, 2019 -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”) today reported business highlights and financial results for its third quarter ended.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For July 19, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Midatech Pharma PLC (NASDAQ: MTP ) shares ...
- GlobeNewswire
Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD
Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that it has dosed the first patient in the ONS-5010-002 Phase 3 clinical trial. “We are pleased to begin dosing patients in the ONS-5010-002 study, our second Phase 3 clinical trial for ONS-5010. This represents the achievement of another important milestone in our streamlined clinical and regulatory strategy, which is designed to support a Biologics License Application, or BLA, submission for ONS-5010 in wet AMD by the end of 2020,” said Lawrence A. Kenyon, President, Chief Executive Officer and Chief Financial Officer.
- Zacks
Hottest Wall Street Stories: What's Up, What's Down
Tariff tantrums hit the broader stock markets last month, leading to the worst May after 2010. Below we discuss these in detail and the impact on the stock world from these events.
- GlobeNewswire
Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of Commercialization Strategy for ONS-5010
Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retinal diseases, today announced that it has signed a master services agreement with FUJIFILM Diosynth Biotechnologies (FDB) for the production of ONS-5010. Under the terms of this agreement, FDB will provide global manufacturing of ONS-5010 to Outlook in support of the commercialization strategy for the drug.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For May 24
Tesla Inc (NASDAQ: TSLA ) shares dropped 2.5 percent to $190.52. The stock rebounded above $200 on Thursday on news of a purported internal email from Musk on the company's fourth-quarter deliveries. ...
- Benzinga
Outlook Therapeutics Rallies 150% In 2 Days: What You Need To Know
Outlook Therapeutics — previously known as Oncobiologics — announced board approval for a 1-for-8 reverse stock split that took effect March 18. This essentially reduced the number of outstanding shares from 94.1 million to 11.8 million. After closing at 91 cents May 15, Outlook shares gap opened Thursday and traded in a $1.15-$1.77 range before ending the session over 68-percent higher at $1.53.
- GlobeNewswire
Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019
CRANBURY, N.J., May 15, 2019 -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported business highlights and financial results for its second fiscal quarter.
- GlobeNewswire
Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical Development
Outlook Therapeutics, Inc. (OTLK) (the “Company”), a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that Jennifer M. Kissner, Ph.D. has joined the Company as Senior Vice President, Clinical Development.
- GlobeNewswire
Outlook Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today the pricing of an underwritten public offering of 10,340,000 shares of its common stock, 15-month warrants to purchase up to an aggregate of 10,340,000 shares of common stock, and 5-year warrants to purchase up to an aggregate of 10,340,000 shares of common stock. BioLexis Pte. Ltd. (BioLexis), the Company’s strategic business partner and largest stockholder, led this financing with a $10 million investment. The shares of common stock and accompanying warrants are being sold at a combined public offering price of $2.75.
- GlobeNewswire
Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010
Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today the U.S. Food and Drug Administration (FDA) acceptance and activation of the Investigational New Drug (IND) application for the Company’s lead product candidate, ONS-5010, an innovative monoclonal antibody (mAb) therapeutic product candidate being developed for wet age related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). The Company is now able to begin enrolling patients with wet AMD in the U.S. portion of its ONS-5010-002 Phase 3 clinical trial.
- GlobeNewswire
Outlook Therapeutics Announces Reverse Stock Split
Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today that its Board of Directors has approved a 1-for-8 reverse stock split of the Company’s common stock, which became effective this morning immediately upon the filing by the Company of a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware. Beginning on March 18, 2019, the Company’s common stock will trade on the Nasdaq Capital Market on a reverse stock split-adjusted basis under the new CUSIP number 69012T206.
- GlobeNewswire
Outlook Therapeutics Regains Compliance With All Nasdaq Listing Requirements
CRANBURY, N.J., March 05, 2019 -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today that the Company received formal notice from The Nasdaq Stock Market.
- GlobeNewswire
Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA
Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today the submission of its Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for ONS-5010. ONS-5010 is an innovative monoclonal antibody (mAb) therapeutic product candidate being developed for wet age related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). Once effective, the IND will allow the Company to begin enrolling patients in the U.S. portion of its ONS-5010-002 Phase 3 clinical trial in patients with wet AMD.
- GlobeNewswire
Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019
CRANBURY, N.J., Feb. 14, 2019 -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported financial results and business highlights for its first fiscal quarter.
- ACCESSWIRE
Healthcare Investment Opportunities You Can't Miss
HENDERSON, NV / ACCESSWIRE / February 13, 2019 / When looking for great growth opportunities to invest in, look no further than the healthcare sector. Healthcare stocks have consistently produced big winners ...
- GlobeNewswire
Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement
CRANBURY, N.J., Feb. 01, 2019 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it closed on the final tranche (of four) of its $20.0 million.
- GlobeNewswire
Outlook Therapeutics Announces Exercise Price Reduction and Term Extension of Series A Warrants
Outlook Therapeutics, Inc. (Nasdaq: OTLK, OTLKW) (the “Company”) today announced that its publicly traded Series A warrants (OTLKW) have been amended to lower the exercise price to $1.50 per share and further extend the maturity until 5:00 p.m. New York City time on February 18, 2022. The Series A warrants were issued as part of the units in its May 2016 initial public offering and in a concurrent private placement and were exercisable for shares of its common stock at an initial exercise price of $6.60 per share. The Series A warrants, as previously extended, would have expired at 5:00 p.m. New York City time on the earlier to occur of (a) the date that was twenty (20) business days after the date on which the closing sales price of the common stock was greater than or equal to $7.25 per share and (b) February 18, 2019.
- GlobeNewswire
Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement
Outlook Therapeutics, Inc. (OTLK) (the “Company”) today announced that it closed on the third tranche (of four) of its $20.0 million private placement of common stock to BioLexis Pte. Limited (BioLexis), the Company’s strategic business partner and largest investor, receiving $4.0 million of cash proceeds in exchange for the issuance of 4,288,624 shares of common stock at $0.9327 per share. The Company has received $16.0 million to date from the sale of its common stock to BioLexis under this private placement, which was previously announced on November 6, 2018. The remaining $4.0 million will be funded on February 1, 2019, subject to achieving certain funding milestones as set forth in the purchase agreement. The Company intends to use the net proceeds from the private placement primarily for clinical trials for its lead product candidate, ONS-5010, and for working capital and general corporate purposes, including agreed repayments on its senior secured notes.
